ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
ChemoCentryx, Inc. (Nasdaq: CCXI) announced that it will release its second quarter 2022 financial results after market close on August 9, 2022. An executive management conference call will take place at 5:00 p.m. ET on the same day to discuss these results. Participants can dial in using provided numbers or access a live webcast via the company’s website. ChemoCentryx specializes in developing new medications for inflammatory and autoimmune diseases, with a focus on TAVNEOS, an oral treatment for ANCA-associated vasculitis.
- Upcoming release of second quarter 2022 financial results may provide key insights into business performance.
- Conference call scheduled for August 9, 2022, allowing investors to engage directly with management.
- None.
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions.
To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (International). The conference ID number is 9726781. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies.
In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe hidradenitis suppurativa (HS) and C3 glomerulopathy (C3G).
ChemoCentryx is also developing CCX559, a highly potent orally administered small molecule PD-L1 checkpoint inhibitor, for the treatment of patients with solid tumors. A Phase I dose escalation study for CCX559 is ongoing and ChemoCentryx plans to advance to a Phase Ib/II study in the second half of 2022.
Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information about the Company visit www.ChemoCentryx.com.
TAVNEOS® is a registered trademark of ChemoCentryx, Inc. For more information, please see the Full Prescribing Information and Medication Guide, available at TAVNEOS.com.
ChemoCentryx Contacts
Investors:
Bill Slattery, Jr.
Vice President, Investor Relations
& Corporate Communications
650.210.2970
bslattery@chemocentryx.com
Media:
Alex Straus
Investor Relations & Corporate
Communications Manager
astraus@chemocentryx.com
FAQ
When will ChemoCentryx announce its second quarter 2022 financial results?
What time is the conference call for ChemoCentryx's financial results?
How can I participate in the ChemoCentryx conference call?
What does ChemoCentryx focus on developing?
